The USA truly is a land of innovation. One adult in eight there is currently taking a GLP-1 drug such as Ozempic or Wegovy.1 Within six months, their households spend 5.3% less on groceries and 8%…
The Legal Board of Appeal has again decided that a divisional application filed after the publication of the mention of grant may be treated as validly filed. The earlier decision to that effect (J 1…
A second medical use patent is often seen as an easy target. The Milan section of the UPC Central Division has just shown that it is much harder to hit when the challenger is required to say exactly…
As readers will be aware, last Thursday, the European Patent Office ("EPO")'s Enlarged Board of Appeal ("EBA") published a new decision (G 1/25) in the saga of referrals seeking guidance on the…
G 1/25, the long-awaited decision on adaptation of the description, was issued today. Adaptation will continue to be required at the EPO, but only if a claim amendment introduces an inconsistency…
This is just a short post on an interesting new development on exceptions to the EPO’s strict approach to admissibility on appeal. T 715/24 reason 2 suggests that claim interpretation is to be…
The most uncomfortable thing one can say about the Unified Patent Court is not that it is becoming too German. It is that it may never have been built, and is still not quite treated, as a European…
G 1/25 addresses a particularly controversial feature of EPO practice: the requirement to adapt the description. The long-anticipated hearing on G 1/25 took place on 8 May 2026, and unfolded in a…
“Never interrupt your enemy when he is making a mistake.” — often attributed to Napoleon, and now, perhaps, to anyone still asking for a stay without a strategy.For years, European patent litigation…